Skip to main content
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Impact of low-income public insurance on survival for children and young adults with bone and soft tissue sarcomas.
Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.
Intestinal obstruction in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
Clinical features, outcomes, and prognostic factors in patients with extraskeletal osteosarcoma.
Solid organ second malignant neoplasms among children diagnosed with malignant bone tumors treated on Children Cancer Study Group/Pediatric Oncology Group protocols after 1980.
Temozolomide and intravenous irinotecan for refractory Ewing’s sarcoma: A retrospective review.
A phase II study of
131
I-MIBG for refractory neuroblastoma.
Cardiovascular risk and sub-clinical atherosclerosis in prostate cancer: patient with and without androgen ablation.
Cardiovascular risk and sub-clinical atherosclerosis in prostate cancer: patient with and without androgen ablation.